Cas No.: | 579492-81-2 |
Chemical Name: | L-Lysine, L-valyl-L-prolyl-L-methionyl-L-leucyl- |
Synonyms: | Val-Pro-Met-Leu-Lys;BIP-V5 |
SMILES: | O=C([C@H](CCC1)N1C([C@@H](N)C(C)C)=O)N[C@@H](CCSC)C(N[C@@H](CC(C)C)C(N[C@H](C(O)=O)CCCCN)=O)=O |
Formula: | C27H50N6O6S |
M.Wt: | 586.7875 |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Bax inhibitor peptide V5 is a Bax-mediated apoptosis inhibitor, used for cancer treatment. |
In Vivo: | V5 (100 μM) significantly improves islet function following isolation and improves islet graft function following transplantation in mice model[2]. |
In Vitro: | Bax inhibitor peptide V5 (0-50 μM) reduces cell death in STF-cMyc cells but not in SW620 or NCI-H23 cells. BIPV5 does not result in any significant effect on cell cycle arrest at the G2/M phase[1]. V5 treatment upregulates expression of anti-apoptotic proteins Bcl-2 and XIAP by more than 3- and 11-fold and downregulates expression of apoptosis-inducing proteins Bax, Bad, and nuclear factor-κB-p65 by 10, 30, and nearly 50%, respectively[2]. |